The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Apricot-P: A randomized placebo-controlled phase II study of COX-2 inhibitor apricoxib or placebo in combination with gemcitabine and erlotinib in advanced or metastatic adenocarcinoma of the pancreas.
Manuel Modiano
No relevant relationships to disclose
George P. Keogh
No relevant relationships to disclose
Robert Manges
No relevant relationships to disclose
Philip J. Stella
No relevant relationships to disclose
Ginger Milne
No relevant relationships to disclose
Ella Looper
Employment or Leadership Position - Tragara Pharmaceuticals
Stock Ownership - Tragara Pharmaceuticals
Sara L. Zaknoen
Employment or Leadership Position - Tragara Pharmaceuticals
Stock Ownership - Tragara Pharmaceuticals